A Nerlyfe ancillary study to describe recurrence in breast cancer patients treated with neratinib in a real-world setting 

Logo Nerlyfe

Multicentre, multi-country, prospective, observational, post-authorisation safety study to describe the incidence of discontinuation due to diarrhoea within the first 3 months of treatment with neratinib, in adult breast cancer patients treated in extended adjuvant in a real-world setting: the NERLYFE study..

Hide study title
Status
Status :
Active not recruiting
Type of study
RWE
Min. Age
18
Years old
Max. Age
-
Gender
Female

Brief summary

HER2+ breast cancer is a subtype of breast cancer which represents approximately 15% to 25% of breast cancer worldwide. In patients with early-stage HER2+ breast cancer, a pivotal clinical study demonstrated that the use of neratinib (Nerlynx®), following (neo)adjuvant trastuzumab based therapy improves clinical outcomes of patients. However, neratinib is known to induce diarrhoea, its’ primary side effect. As a consequence, pharmacovigilance activity is performed to better characterise and minimise the risks of diarrhoea associated with the neratinib administration.
In this context, the purpose of this observational, prospective study is to describe the diarrhoea related discontinuations during the use of extended adjuvant neratinib in the real-world setting.

Therapeutic area :
Oncology
Disease :
Breast cancer
Study medication :
Neratinib (NERLYNX®)
Phase : RWE
Start Date :
May 08, 2022
End Date / study Completion Date :
January 2026
Study ID : NIS12501
CT.gov Number : EUPAS41584
Countries :
Austria
Czech Republic
Germany
United Kingdom

Contact Us

Need more information , click on the button to have access to the contact form.

Contact Us

Access to Lay Protocol Synopsis

A summary of the protocol written in plain language and describing the objectives of the study is provided. 

Send by email